Rolf Kiessling

The group of Rolf Kiessling is active both in basic and clinical tumor immunology research.

His clinical research is facilitated by his part time position (25%) as a consultant physician in the melanoma unit at the Oncology clinic. The group has participated as principal investigator or co-investigator in several investigator initiated clinical trials, of which many originates from basic research projects in his lab. The investigator initiated trials includes tumor vaccine trials based on pDNA in prostate- or breast cancer patients, Dendritic cell based trial in patients with gastric cancer and malignant melanoma, anti-oxidant treatment of patients with colorectal cancer, peptide based tumor vaccine in patients with ovarian cancer and currently a trial involving treatment of advanced melanoma patients with a combination of TIL cells and a DC tumor vaccine. Several of his current trials are carried out in close collaboration with clinicians at the Oncology clinic at Karolinska hospital and with Jonas Mattsson and Markus Maeurer at the CAST unit, Huddinge.

Selected publications

Mougiakakos, D.; Johansson, C. C.; Jitschin, R.; Bottcher, M.; Kiessling, R.

Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress.

Blood 2011, 117 (3), 857-61

Triulzi, C.; Vertuani, S.; Curcio, C.; Antognoli, A.; Seibt, J.; Akusjarvi, G.; Wei, W. Z.; Cavallo, F.; Kiessling, R.

Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors.

Cancer Res 2010, 70 (19), 7431-41

Poschke, I.; Mougiakakos, D.; Hansson, J.; Masucci, G. V.; Kiessling, R.

Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.

Cancer Res 2010, 70 (11), 4335-45

Mougiakakos, D.; Johansson, C. C.; Kiessling, R.

Naturally occurring regulatory T cells show reduced sensitivity toward oxidative stress-induced cell death.

Blood 2009, 113 (15), 3542-5

Norell, H.; Carlsten, M.; Ohlum, T.; Malmberg, K. J.; Masucci, G.; Schedvins, K.; Altermann, W.; Handke, D.; Atkins, D.; Seliger, B.; Kiessling, R.

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Cancer Res 2006, 66 (12), 6387-94

Holmgren, L.; Ambrosino, E.; Birot, O.; Tullus, C.; Veitonmaki, N.; Levchenko, T.; Carlson, L. M.; Musiani, P.; Iezzi, M.; Curcio, C.; Forni, G.; Cavallo, F.; Kiessling, R

DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth.

Proc Natl Acad Sci U S A 2006, 103 (24), 9208-13

Choudhury, A.; Charo, J.; Parapuram, S. K.; Hunt, R. C.; Hunt, D. M.; Seliger, B.; Kiessling, R.

Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines.

Int J Cancer 2004, 108 (1), 71-7

Nakagomi, H.; Petersson, M.; Magnusson, I.; Juhlin, C.; Matsuda, M.; Mellstedt, H.; Taupin, J. L.; Vivier, E.; Anderson, P.; Kiessling, R.

Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma.

Cancer Res 1993, 53 (23), 5610-2

Kärre, K.; Ljunggren, H.-G.; Piontek, G. E.; Kiessling, R.

Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defense strategy.

Nature 1986, 319, 675-678

Kiessling, R.; Hochman, P. S.; Haller, O.; Shearer, G. M.; Wigzell, H.; Cudkowicz, G.

Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts.

Eur J Immunol 1977, 7 (9), 655-63

Kiessling, R.; Klein, E.; Pross, H.; Wigzell, H.

"Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell.

Eur J Immunol 1975, 5 (2), 117-21

Last modified by: Monica Ringheim 2012-06-01